{"name":"Cybrexa Therapeutics","slug":"cybrexa-therapeutics","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxNTjZGNEtXNVFxV0FucWNPSUlNMTF5XzNGZWctT2ZGMWpwT25XMURfLU1TcmRTc0s1eXNQQUdVOVRfaXppcVg3YV8wYzE1ZVZVY2toUElYakNMSHB5cXhsVTNzeGhCYVM0ckFybG1IbjRJTUtHazVHQ3BPQ0tTM0U2S0NtYzJrdGxDN1RoRQ?oc=5","date":"2025-05-12","type":"pipeline","source":"The ASCO Post","summary":"In Case You Missed It: Additional Abstracts of Interest From AACR - The ASCO Post","headline":"In Case You Missed It: Additional Abstracts of Interest From AACR","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxQU1JQMGpPZjRmSldFWUJxUUNocE05LXU4VV9PdVp5U2V3cDJVa1YtRXRIYjlhbWdHY3d5a0dCd1NUUnhOUGlnRGYzcWk5d3N2eEpzNzJya21WWFRvcHBjNG1ITk5OQjFxOHl0Y3l5TXV5dGhaUDlSaWtfQ09pSGlhdWFCMmJnUHFyRG1mVU5oSVdDQQ?oc=5","date":"2025-04-21","type":"pipeline","source":"Insightace Analytic","summary":"Peptide�drug Conjugates (PDCs) Market Share, Size, Growth and Forecast to 2034 - Insightace Analytic","headline":"Peptide�drug Conjugates (PDCs) Market Share, Size, Growth and Forecast to 2034","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwJBVV95cUxNdWp0R1lMQkF5Q1NtRDQ5YTVlaG1tUnhOVFp2eGlWVnV1WTJ6THF4NE5TOGJwR18xNGRkTGJRZnlkMmw5TUNkS1F4RzNzRFpvUlBmdUUwRGE5aFBUUV95STEyN1hKS3Q1WG1FaUdqVnFxa2UzV2RZb1BkcXA4VzJ4M2s5aGlMTFo2ZmxpTEliS3l5WEJSc1Q4QTB1WVNFSEFTZ3Z2TV9CaVZhLVZYaDFJSnlCWHdaM0pCV0U3YldtT291UTVhMmlDQjBlc1U0ZDJMWVhRc2xxR25zSVliTTcwcnpnQ1Y1OEdNbUVYa0hMMUZtYUJVOHpmRnltMWY5NXZibzBfbl9GMk1yTzNobVZreVQyOWJFcDRCaXlwcUc1SDVGdC1TbFJ5RXJuN0lzLU1SbVMxWEw3SnNoczRrdVJZ?oc=5","date":"2025-03-04","type":"trial","source":"GlobeNewswire","summary":"Cybrexa Therapeutics Announces New Preclinical Data on - GlobeNewswire","headline":"Cybrexa Therapeutics Announces New Preclinical Data on","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxOcUlQTUJfYUhhNk9VZXNXQ3JWYlExd0hqYzkyOW5HV2htMmlzQXE1akZKbFJFTzNHTmo4VWVjdFctUjZfRW1mOGVPcmdIcDdJTzhZSW5YWTB5VURpWlFPTG9Sd05OS0pnTWpkc3RQdDdmSXo0T2F5eVhINHc4MF8tUTVyXzBMTHpRZEk1blZ0SkV1YWFXaE1TRVEwRVJ6Q3B3MlJoTC1fWnJmQ21SQ0MydFIwMjNlMWpXS08tZ01paU9Da2QyRUtCdU94cWFEQ1N6enNURGQ3WGstNWxieVVlblNteHM2OVd0M3c?oc=5","date":"2025-02-04","type":"pipeline","source":"PR Newswire","summary":"Global Peptide-Drug Conjugate Market to Show Enormous Growth at a CAGR of ~29% by 2032 | DelveInsight - PR Newswire","headline":"Global Peptide-Drug Conjugate Market to Show Enormous Growth at a CAGR of ~29% by 2032 | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTE1PYkNXYU1xNGlyX0J2MkczWWt6ckFUNWFwLUJwX1hSaXpvNGlkUnhNUDBrYllvNmlvbGlxcGEteFBXUHlyTzdLX08wdTFlV1NTRXc2aGtpSjVNU0N0TVF1RlVxcUVnNVlKSUNHMHpzTEU5dXhX?oc=5","date":"2024-06-29","type":"pipeline","source":"The Pharma Letter","summary":"Cybrexa Therapeutics - The Pharma Letter","headline":"Cybrexa Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxOd0lqSFRMR1lzR094SzZxZm56NEZNeGhfN3R1VEp3VnpDclp6ZlNYZEF5UTBGNy16Y2Q1RWpOdENkY3RibWJHbnpiYkltRGZRdVBWNTh4akpkZEQ5X3NUdVhzeHFxTHdocER6TmR4S0VzU0dsX3U3LWZGZkZxVE53X3ZBU2wwMFlVcXBFeEt6U0I1UlZxTHpvRW1jb1Z6NFpmSE1MalBOWlc?oc=5","date":"2023-04-19","type":"trial","source":"Oncology News Central","summary":"Dual Inhibition of PARP and ATR Feasible, Early Trials Suggest - Oncology News Central","headline":"Dual Inhibition of PARP and ATR Feasible, Early Trials Suggest","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxNY21kVGVOQ1M3dlZ0OTZpeGtpQnZhaGxnbmc2MHRCSzIzakxDcUF3YjlVNkl3Um5zN0JaT2g4U1Vpamc5LU1sQWpwQm1UNWtWU1djaFR5WC1tTllUY3FwUXU1QnAtQ3o3NS0yUVF3anR2WHY1dnlWT0dDNlhxWUhaV2J5UkUtV1NPa1BDZmQtX19zUl9OcWQtZDFxTWpaeXNzc2JLdVM4SFVmTERW?oc=5","date":"2022-11-03","type":"deal","source":"Fierce Biotech","summary":"3 is the magic number: Exelixis' 3rd deal in 3 days offers $30M for 3 Catalent programs - Fierce Biotech","headline":"3 is the magic number: Exelixis' 3rd deal in 3 days offers $30M for 3 Catalent programs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxOUGdfaEMzaG53RDNyV1A4VnE4aG9JbVk2NS12NV9taDdYQVVoamIwTEZuaWR0MFBwQVVtN1JQVXdCY2JORFI1RjBzTmh1OUo0NVk4c05ZUE1wd0hkeGN6c24zdVN4LTZ5R2h5R2xhSGxPOU5qTm91TjVHYVc1OUpsVkZWRDdjbG1pdVR3aWdwN3NDeThPWHQ0RGxHQjlyR1dmelE?oc=5","date":"2022-11-01","type":"deal","source":"Fierce Biotech","summary":"Busy day for Exelixis with 2 new deals worth up to $937M-plus in biobucks - Fierce Biotech","headline":"Busy day for Exelixis with 2 new deals worth up to $937M-plus in biobucks","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxPUkwzLUdIUFA4RWRQWVUyb181TmphQjZ0MnByYXRNRGRvbm5HSVMzWHdVMzlUcVZEcjFzUlZZQTgwREluU0JLWmFXcV9GWGplcXhYMlRpaVIyUmpaMjlROG9CdjNVVk9ESi1nQ0lZbGJTSzJnSWd0QWxnVXJzZ25RRzBQVVFFUHNhRC1faEJaT21uZXM?oc=5","date":"2022-10-10","type":"pipeline","source":"Grand View Research","summary":"Peptide Drug Conjugates Market Size | Industry Report, 2030 - Grand View Research","headline":"Peptide Drug Conjugates Market Size | Industry Report, 2030","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxPWkd2bWZIbndIeUFlZEFXN21BUy1FMUk1WUFvbTIza1QwYkQzTUxHc29YUGxOai15aXhsRG41R0ZfLUhiU3I0LWp6d2xyZHQ2a0NUZ2hHYnJYZms3QkV6bUtGaG5uSVRpaFgwRUdDTTRnSk5TbWIxSzkyeHJQVGxZYnA2dmk1a0tWTGx1bFpYMEt3UUVLRWxpaEVTS212dWNBZEdNWA?oc=5","date":"2022-01-17","type":"pipeline","source":"BioSpace","summary":"Cybrexa is Disrupting the ADC Market with Peptide Drug Conjugate Therapeutics - BioSpace","headline":"Cybrexa is Disrupting the ADC Market with Peptide Drug Conjugate Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxONTV2RnIzSXZBVWR1Zlo1Q2JUbkFtVXc3SEdSVjlScEdRcnlLNGV4T2FZSWtORF82elg5RDhXNDZtaFJsZjNTYy1HYVBuWHlhbjBxQWxWLUxzTlV5aU5SejZ0UjZ5czlWSkRVRjZkU1RYbng3dlNheUFFQXhVOURWZmpQVElLMmtsdXZDRGNNMUNQaUpncUFBamRTTUVPLVJTZDlMa2FrYW9POVFLZ21zMUVkMkJWeW9IbnZEdHVKZmI2cm9uS2ZpUnVtT1NIYzQ?oc=5","date":"2021-06-05","type":"pipeline","source":"Healio","summary":"Selective glutaminase-1 inhibitor shows antitumor activity across cancer types - Healio","headline":"Selective glutaminase-1 inhibitor shows antitumor activity across cancer types","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}